RGNX REGENXBIO Inc.
QT30| Index | — | P/E | — | EPS (ttm) | -3.79 | Insider Own | 6.96% | Shs Outstand | 66.01M | Perf Week | 8.81% |
| Market Cap | 472.65M | Forward P/E | — | EPS next Y | -2.74 | Insider Trans | 0.63% | Shs Float | 57.23M | Perf Month | -3.63% |
| Enterprise Value | 428.65M | PEG | — | EPS next Q | -1.29 | Short Float | 17.55% | Perf Quarter | -30.49% | ||
| Income | -196.00M | P/S | 2.72 | EPS this Y | — | Short Ratio | 7.28 | Perf Half Y | -23.75% | ||
| Sales | 174.00M | P/B | 6.56 | EPS next Y | — | ROA | -50.81% | Short Interest | 10.04M | Perf YTD | -50.28% |
| Book/sh | 1.09 | P/C | 4.46 | EPS next 5Y | — | ROE | -220.07% | 52W High | 16.19 -55.78% | Perf Year | -44.15% |
| Cash/sh | 1.61 | P/FCF | — | EPS past 3/5Y | — | ROIC | -52.72% | 52W Low | 5.46 31.14% | Perf 3Y | -53.36% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 14.58% 1.86% | Gross Margin | 54.22% | Volatility | 7.12% 6.54% | Perf 5Y | -80.41% |
| Dividend TTM | — | EV/Sales | 2.46 | EPS Y/Y TTM | — | Oper. Margin | -94.08% | ATR (14) | 0.49 | Perf 10Y | -57.63% |
| Dividend Ex-Date | — | Quick Ratio | 2.86 | Sales Y/Y TTM | 12.26% | Profit Margin | -112.58% | RSI (14) | 45.86 | Recom | 2.35 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.86 | EPS Q/Q | 131.16% | SMA20 | -1.22% | Beta | 1.19 | Target Price | 20.00 |
| Payout | 0.00% | Debt/Eq | 0.86 | Sales Q/Q | 414.29% | SMA50 | -9.50% | Rel Volume | 0.75 | Prev Close | 7.20 |
| Employees | 371 | LT Debt/Eq | 0.86 | Earnings | Nov 05 | SMA200 | -21.64% | Avg Volume | 1.37M | Price | 7.16 |
| IPO Date | Sep 17, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 446.19% 10.64% | Net Debt/EBITDA | — | Volume | 1,029,332 | Change | -0.56% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-05-26 | Initiated | Mizuho | Outperform | $22 |
| Aug-25-26 | Reiterated | Robert W. Baird | $32 → $29 | |
| Aug-25-26 | Reiterated | HC Wainwright & Co. | Buy | $23 → $21 |
| Aug-10-26 | Reiterated | HC Wainwright & Co. | Buy | $26 → $23 |
| Aug-07-26 | Reiterated | Morgan Stanley | Overweight | $16 → $18 |
| Aug-07-26 | Downgrade | Barclays | Overweight → Equal Weight | |
| Jul-01-26 | Reiterated | H.C. Wainwright | Buy | $30 → $26 |
| Jun-22-26 | Reiterated | Robert W. Baird | $27 → $32 | |
| Jun-22-26 | Reiterated | Leerink Partners | Outperform | $20 → $18 |
| May-15-26 | Reiterated | Morgan Stanley | Overweight | $17 → $16 |
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 174 | 170 | 83 | 90 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 80 | 20 | 34 | 37 | — | — | — | — | — | |
| Gross Profit | 94 | 150 | 50 | 53 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 85 | 83 | 77 | 88 | — | — | — | — | — | |
| Research and Development | 229 | 228 | 209 | 232 | — | — | — | — | — | |
| Other Operating Expense | -55 | 0 | -3 | 1 | — | — | — | — | — | |
| Operating Income | -164 | -161 | -233 | -268 | — | — | — | — | — | |
| Interest Expense | 42 | 45 | 13 | 7 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 10 | 12 | 19 | 11 | — | — | — | — | — | |
| Net Income Before Taxes | -196 | -194 | -227 | -264 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -196 | -194 | -227 | -263 | — | — | — | — | — | |
| Net Income From Continuing Operations | -196 | -194 | -227 | -263 | — | — | — | — | — | |
| Net Income | -196 | -194 | -227 | -263 | — | — | — | — | — | |
| EPS (Recurring) | -3.79 | -3.76 | -4.59 | -6.02 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.79 | -3.76 | -4.59 | -6.02 | — | — | — | — | — | |
| EPS (Diluted) | -3.79 | -3.76 | -4.59 | -6.02 | — | — | — | — | — | |
| EBITDA | -139 | -133 | -198 | -239 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.18 | 4.40 | 4.66 | 8.78 | — | — | — | — | — | |
| Gross Margin | 54.02 | 88.24 | 60.24 | 58.89 | — | — | — | — | — | |
| Operating Margin | -94.25 | -94.71 | -280.72 | -297.78 | — | — | — | — | — | |
| Net Margin | -112.64 | -114.12 | -273.49 | -292.22 | — | — | — | — | — | |
| Shares Outstanding | 53 | 52 | 50 | 44 | — | — | — | — | — | |
| Market Capitalization | 379 | 749 | 387 | 790 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director | Aug 27 '26 | Buy | 9.36 | 53,407 | 499,676 | 118,035 | Aug 27 |
| Ciongoli Gregory Austin | Director | Aug 26 '26 | Buy | 9.14 | 49,196 | 449,706 | 64,628 | Aug 27 |
| PAKOLA STEVE | Chief Medical Officer | Jul 02 '26 | Option Exercise | 7.86 | 2,161 | 16,985 | 215,170 | Jul 06 |
| PAKOLA STEVE | Chief Medical Officer | Jul 02 '26 | Sale | 13.64 | 2,161 | 29,476 | 213,009 | Jul 06 |
| PAKOLA STEVE | Chief Medical Officer | Jul 01 '26 | Sale | 12.86 | 36,725 | 472,284 | 213,009 | Jul 01 |
| PAKOLA STEVE | Chief Medical Officer | Jul 01 '26 | Option Exercise | 7.86 | 36,725 | 288,659 | 249,734 | Jul 01 |
| PAKOLA STEVE | Chief Medical Officer | Jun 29 '26 | Sale | 11.04 | 19,608 | 216,472 | 213,009 | Jul 01 |
| PAKOLA STEVE | Chief Medical Officer | May 11 '26 | Sale | 11.02 | 15,309 | 168,705 | 232,617 | May 13 |
| PAKOLA STEVE | Chief Medical Officer | Mar 10 '26 | Sale | 10.35 | 5,124 | 53,033 | 247,926 | Mar 12 |
| Mills Kenneth T. | Director | Jan 27 '26 | Option Exercise | 13.09 | 225,000 | 2,945,250 | 707,871 | Jan 29 |
| Simpson Curran | Chief Executive Officer | Oct 09 '25 | Sale | 12.62 | 20,811 | 262,635 | 216,162 | Oct 10 |
| Simpson Curran | Chief Executive Officer | Sep 29 '25 | Sale | 10.03 | 7,624 | 76,469 | 236,973 | Oct 01 |
| Simpson Curran | Chief Executive Officer | Sep 10 '25 | Sale | 10.02 | 7,734 | 77,495 | 244,597 | Sep 12 |
| Mills Kenneth T. | Director | May 12 '25 | Option Exercise | 3.76 | 20,602 | 77,464 | 495,705 | May 14 |
| Mills Kenneth T. | Director | May 12 '25 | Sale | 7.91 | 20,602 | 163,046 | 475,103 | May 14 |